BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31366619)

  • 1. High frequency of inactivating tetraspanin
    Elfrink S; de Winde CM; van den Brand M; Berendsen M; Roemer MGM; Arnold F; Janssen L; van der Schaaf A; Jansen E; Groenen PJTA; Eijkelenboom A; Stevens W; Hess CJ; van Krieken JH; Vermaat JSP; Cleven AHG; de Groen RAL; Neviani V; de Jong D; van Deventer S; Scheijen B; van Spriel AB
    Blood; 2019 Sep; 134(12):946-950. PubMed ID: 31366619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.
    Elfrink S; Ter Beest M; Janssen L; Baltissen MP; Jansen PWTC; Kenyon AN; Steen RM; de Windt D; Hagemann PM; Hess C; van Spronsen DJ; Hoevenaars B; van der Spek E; Xu-Monette ZY; Young KH; Kaffa C; Bervoets S; van Heek J; Hesius E; de Winde CM; Vermeulen M; van den Brand M; Scheijen B; van Spriel AB
    Blood Adv; 2022 Apr; 6(7):2254-2266. PubMed ID: 35086136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.
    King RL; Goodlad JR; Calaminici M; Dotlic S; Montes-Moreno S; Oschlies I; Ponzoni M; Traverse-Glehen A; Ott G; Ferry JA
    Virchows Arch; 2020 May; 476(5):647-665. PubMed ID: 31863183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
    Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
    J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetraspanin CD37 protects against the development of B cell lymphoma.
    de Winde CM; Veenbergen S; Young KH; Xu-Monette ZY; Wang XX; Xia Y; Jabbar KJ; van den Brand M; van der Schaaf A; Elfrink S; van Houdt IS; Gijbels MJ; van de Loo FA; Bennink MB; Hebeda KM; Groenen PJ; van Krieken JH; Figdor CG; van Spriel AB
    J Clin Invest; 2016 Feb; 126(2):653-66. PubMed ID: 26784544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
    Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system.
    Jordanova ES; Riemersma SA; Philippo K; Schuuring E; Kluin PM
    Int J Cancer; 2003 Jan; 103(3):393-8. PubMed ID: 12471623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary lymphoma of the central nervous system: just DLBCL or not?
    Montesinos-Rongen M; Siebert R; Deckert M
    Blood; 2009 Jan; 113(1):7-10. PubMed ID: 18802010
    [No Abstract]   [Full Text] [Related]  

  • 13. Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration.
    Gartlan KH; Wee JL; Demaria MC; Nastovska R; Chang TM; Jones EL; Apostolopoulos V; Pietersz GA; Hickey MJ; van Spriel AB; Wright MD
    Eur J Immunol; 2013 May; 43(5):1208-19. PubMed ID: 23420539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation.
    Cambruzzi E
    World Neurosurg; 2020 Feb; 134():215-220. PubMed ID: 31605845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses.
    Zuckerman NS; McCann KJ; Ottensmeier CH; Barak M; Shahaf G; Edelman H; Dunn-Walters D; Abraham RS; Stevenson FK; Mehr R
    Int Immunol; 2010 Nov; 22(11):875-87. PubMed ID: 21059768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling axis and supports long-lived plasma cell survival.
    van Spriel AB; de Keijzer S; van der Schaaf A; Gartlan KH; Sofi M; Light A; Linssen PC; Boezeman JB; Zuidscherwoude M; Reinieren-Beeren I; Cambi A; Mackay F; Tarlinton DM; Figdor CG; Wright MD
    Sci Signal; 2012 Nov; 5(250):ra82. PubMed ID: 23150881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD37 expression in follicular lymphoma.
    Yoshimura T; Miyoshi H; Shimono J; Nakashima K; Takeuchi M; Yanagida E; Yamada K; Shimasaki Y; Moritsubo M; Furuta T; Kohno K; Ohshima K
    Ann Hematol; 2022 May; 101(5):1067-1075. PubMed ID: 35171311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.